NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only

NSABP Foundation, Inc.

General NSABP Information
  Financial Conflicts of
     Interest Policy
  Contact the NSABP

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-51
  Protocol B-52
  Protocol B-53/S1207
  Protocol B-55/BIG 6-13

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR

To report problems, ask
questions or make comments,
please send e-mail to:

NSABP Clinical Trials Overview

Protocol B-15
A Three-Arm Clinical Trial Comparing Short, Intensive Adriamycin-Cyclophosphamide Chemotherapy With and Without Interval Reinduction Chemotherapy (CMF) to "Conventional" CMF in Positive-Node Patients Having The Following Age and Receptor Criteria:
49 Years or younger - All Patients
50-59 Years - PR<10 fmol, regardless of ER

Specific Aims
To determine, in patients with histologically positive axillary nodes who are not classified as tamoxifen-responsive, whether short, intensive adjuvant chemotherapy (AC, with or without interval reinduction with CMF) is as effective as or more effective than "conventional" CMF with respect to disease-free survival and survival.